The categorical definition of response assessed via the Response Evaluation Criteria in Solid Tumors has documented limitations. We sought to identify alternative metrics for tumor response that improve prediction of overall survival
Purpose To investigate Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) approxi...
AbstractBackgroundThe high failure rate in phase III oncology trials is partly because the signal ob...
The major end-points arising from cancer clinical trials are reviewed. These are: tumour response, t...
The categorical definition of response assessed via the Response Evaluation Criteria in Solid Tumors...
Introduction: Longitudinal tumor measurements (TM) are commonly recorded in cancer clinical trials o...
In February 2000, the criteria for measuring tumor shrinkage as an indicator of antitumor activity w...
International audienceBackground Response Evaluation Criteria in Solid Tumors (RECIST) are widely us...
Importance: Tumor measurements can be used to estimate time to nadir and depth of nadir as potential...
Patients with certain cancers are treated with curative intent, but for others the results are less ...
The decision to use a given type of chemotherapy to treat cancer patients is often based on the prio...
(RECIST 1.1) guideline states that the two largest lesions per organ should be measured as target le...
IntroductionResponse-assessment metrics play an important role in clinical trials and routine patien...
International audiencePurpose: To compare the agreement of three-dimensional (3D) tumor ă measuremen...
Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses t...
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Respons...
Purpose To investigate Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) approxi...
AbstractBackgroundThe high failure rate in phase III oncology trials is partly because the signal ob...
The major end-points arising from cancer clinical trials are reviewed. These are: tumour response, t...
The categorical definition of response assessed via the Response Evaluation Criteria in Solid Tumors...
Introduction: Longitudinal tumor measurements (TM) are commonly recorded in cancer clinical trials o...
In February 2000, the criteria for measuring tumor shrinkage as an indicator of antitumor activity w...
International audienceBackground Response Evaluation Criteria in Solid Tumors (RECIST) are widely us...
Importance: Tumor measurements can be used to estimate time to nadir and depth of nadir as potential...
Patients with certain cancers are treated with curative intent, but for others the results are less ...
The decision to use a given type of chemotherapy to treat cancer patients is often based on the prio...
(RECIST 1.1) guideline states that the two largest lesions per organ should be measured as target le...
IntroductionResponse-assessment metrics play an important role in clinical trials and routine patien...
International audiencePurpose: To compare the agreement of three-dimensional (3D) tumor ă measuremen...
Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses t...
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Respons...
Purpose To investigate Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) approxi...
AbstractBackgroundThe high failure rate in phase III oncology trials is partly because the signal ob...
The major end-points arising from cancer clinical trials are reviewed. These are: tumour response, t...